STAT+: Pharmalittle: We’re reading about Lilly ‘black market’ lawsuits, pushback over Trump vaccine plan, and more
Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide
Hello, everyone, and I hope you are doing well today. After surviving the middle of the week, we are determined to make the most of the remaining days. To keep ourselves occupied, we have a delightful flavor for you today: butter pecan. We trust you are having a wonderful day and please do stay in touch.
Recently, a group of physicians and Prader-Willi syndrome experts have alerted healthcare professionals about a series of patient deaths and severe side effects potentially linked to Vykat XR, a recently approved drug by Neurocrine Biosciences. According to the FDA's Adverse Event Monitoring System, seven individuals prescribed Vykat have tragically passed away, while over 100 reports of serious adverse events have been filed, primarily involving hospitalizations for swelling, respiratory, and heart complications.
Eli Lilly has taken a strong stance against the unauthorized sale of its experimental obesity drug, retatrutide, by filing six lawsuits against U.S. companies. These businesses, including compounding pharmacies, medical spas, and online sellers, allegedly marketed retatrutide to consumers even though the drug is still in Phase 3 clinical trials for obesity, type 2 diabetes, and related conditions. Retatrutide remains under regulatory approval.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — it may contain errors, so check the original before relying on it.
